IMUC Update Adds Clarity and Further Validates Investment Thesis
ImmunoCellular Update Adds Clarity and Further Validates Investment Thesis
(search via google =propthink IMUC)
....Preparing for Success
Immunocellular have brought a second manufacturing site online for ICT-107 to advance the ability to meet the needs of further clinical testing and commercial manufacturing. Mr Gengos stated that the ImmunoCellular strategy over the next three to five years is to build an independent oncology company and to potentially go it alone in the U.S. for ICT-107. The language has changed, from previously talking about the need for a Phase III trial, to meeting the FDA post-Phase II with the data. There is a real possibility that the data will be good enough to support accelerated approval, or at the very least, compassionate use. ImmunoCellular are making background moves with “a commercialization readiness assessment” as well as to identify “we’re going to identify the gaps that we have between our position today and what we would need to fill in order to both conduct a Phase III trial as well as to commercialize ICT-107.” We anticipate that between now and the end of the year, ImmunoCellular’s share price, barring any unforeseen complications, will climb from the mid-$2’s to the $6-8 range ahead of the top-line data and as more investors get acquainted with IMUC and ICT-107’s potential. This would still represent a market capitalization of under $500M – with the possibility of an easy double on impressive Phase II data.